BACKGROUND: The immune system has been shown to play an important role in gastrointestinal stromal tumor (GIST). The neutrophil-to-lymphocyte ratio (NLR) in blood is an easily assessable parameter of systemic inflammatory response. The aim of this study was to determine whether the NLR is prognostic in GIST. METHODS: A total of 339 previously untreated patients with primary, localized GIST operated at our institution between 1995 and 2010 were identified from a prospectively collected sarcoma database. NLR was assessed preoperatively. Patients who received adjuvant imatinib treatment were excluded from the analysis (n = 64). Cox regression models were calculated and correlation analyses were performed. RESULTS: On univariate analysis, NLR was associated with recurrence-free survival (RFS) (P = 0.003, hazard ratio 3.3, 95 % confidence interval 1.5-7.4). Patients with a low NLR had a 1- and 5-year RFS of 98 and 91 %, compared with 89 and 76 % in those with a high NLR. The median RFS was not reached. Positive correlations were found between NLR and mitotic rate (Pearson correlation coefficient [r] = 0.15, P = 0.03), and NLR and tumor size (r = 0.36, P = 0.0001). RFS in patients with a GIST >5 cm with low NLR was significantly longer compared to patients with high NLR (P = 0.002). Flow cytometry analysis of freshly obtained GISTs revealed that neutrophils constituted a minimal percentage of intratumoral immune cells. CONCLUSIONS: NLR is a surrogate for high-risk tumor features. Elevated blood NLR appears to represent systemic inflammation in patients with high-risk GIST.
BACKGROUND: The immune system has been shown to play an important role in gastrointestinal stromal tumor (GIST). The neutrophil-to-lymphocyte ratio (NLR) in blood is an easily assessable parameter of systemic inflammatory response. The aim of this study was to determine whether the NLR is prognostic in GIST. METHODS: A total of 339 previously untreated patients with primary, localized GIST operated at our institution between 1995 and 2010 were identified from a prospectively collected sarcoma database. NLR was assessed preoperatively. Patients who received adjuvant imatinib treatment were excluded from the analysis (n = 64). Cox regression models were calculated and correlation analyses were performed. RESULTS: On univariate analysis, NLR was associated with recurrence-free survival (RFS) (P = 0.003, hazard ratio 3.3, 95 % confidence interval 1.5-7.4). Patients with a low NLR had a 1- and 5-year RFS of 98 and 91 %, compared with 89 and 76 % in those with a high NLR. The median RFS was not reached. Positive correlations were found between NLR and mitotic rate (Pearson correlation coefficient [r] = 0.15, P = 0.03), and NLR and tumor size (r = 0.36, P = 0.0001). RFS in patients with a GIST >5 cm with low NLR was significantly longer compared to patients with high NLR (P = 0.002). Flow cytometry analysis of freshly obtained GISTs revealed that neutrophils constituted a minimal percentage of intratumoral immune cells. CONCLUSIONS: NLR is a surrogate for high-risk tumor features. Elevated blood NLR appears to represent systemic inflammation in patients with high-risk GIST.
Authors: Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Hohenberger; Isabelle Ray-Coquard; Marcus Schlemmer; Allan T van Oosterom; David Goldstein; Raf Sciot; Pancras C W Hogendoorn; Michelle Brown; Rossella Bertulli; Ian R Judson Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura Journal: Science Date: 1998-01-23 Impact factor: 47.728
Authors: Frede Donskov; Karen Marie Bennedsgaard; Marianne Hokland; Niels Marcussen; Rune Fisker; Hans Henrik Torp Madsen; Kirsten Fode; Hans von der Maase Journal: Cancer Immunol Immunother Date: 2004-04-15 Impact factor: 6.968
Authors: Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: Science Date: 2003-01-09 Impact factor: 47.728
Authors: Cristina R Antonescu; Agnes Viale; Lisa Sarran; Sylvia J Tschernyavsky; Mithat Gonen; Neil H Segal; Robert G Maki; Nicholas D Socci; Ronald P DeMatteo; Peter Besmer Journal: Clin Cancer Res Date: 2004-05-15 Impact factor: 12.531
Authors: H Schmidt; L Bastholt; P Geertsen; I J Christensen; S Larsen; J Gehl; H von der Maase Journal: Br J Cancer Date: 2005-08-08 Impact factor: 7.640
Authors: Süleyman Kargın; Murat Çakır; Ebubekir Gündeş; Yusuf Yavuz; Hacı Hasan Esen; M Sinan İyisoy; Naile Kökbudak; Tevfik Küçükkartallar Journal: Ulus Cerrahi Derg Date: 2015-06-01
Authors: Jeremy L Davis; Russell C Langan; Katherine S Panageas; Junting Zheng; Michael A Postow; Mary S Brady; Charlotte Ariyan; Daniel G Coit Journal: Ann Surg Oncol Date: 2017-03-16 Impact factor: 5.344
Authors: Brian Hung-Hin Lang; Cathy Po-Ching Ng; Kin Bun Au; Kai Pun Wong; Kandy K C Wong; Koon Yat Wan Journal: World J Surg Date: 2014-10 Impact factor: 3.352
Authors: Sam C Wang; Joanne F Chou; Vivian E Strong; Murray F Brennan; Marinela Capanu; Daniel G Coit Journal: Ann Surg Date: 2016-02 Impact factor: 12.969